Target- |
Mechanism- |
|
|
Active Indication- |
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.
100 Clinical Results associated with Quivive Pharma, Inc.
0 Patents (Medical) associated with Quivive Pharma, Inc.
100 Deals associated with Quivive Pharma, Inc.
100 Translational Medicine associated with Quivive Pharma, Inc.